Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, September 1, 2014. To access the conference call, follow these instructions:
Dial: (877) 881.2183 (U.S.); (970) 315.0453 (international)
Passcode: 73168608 (Nektar Therapeutics is the host)In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About NektarNektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugate technology platform. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Movantik™ (naloxegol), an investigational drug candidate, which has been filed for regulatory approvals in the U.S., Europe and Canada as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes Movantik fixed dose combination products (formerly NKTR-119), an earlier stage development program that is a co-formulation of Movantik and an opioid. NKTR-181, a novel mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development. NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain, is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatm
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... N.C. , Oct. 24, 2014 ... provide Medical Affairs leaders with a forum for ... The consortium has developed a mechanism for creating ... where leaders discuss key findings from the Medical ... has completed the analysis for the first roundtable ...
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation ... introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), the first ... systems designed and manufactured by Cephasonics for purchase by ... model number. Cephasonics will be showcasing the cQUB-1 for ... this week in Chongqing, China ...
(Date:10/22/2014)... Investor-Edge has initiated coverage on the following ... Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), Threshold ... Inc. (NASDAQ: IDRA ), and Merrimack Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,419.48, up 2.40%, the Dow Jones Industrial Average ...
Breaking Medicine Technology:Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
(Date:10/25/2014)... October 25, 2014 Triton Algae ... today announced Dr. Xun Wang has joined ... & Development. , Triton has developed a patented synthetic ... proteins. According to Dr. Wang, the platform uses algae ... systems. He says, “Algae are unique because they can ...
(Date:10/25/2014)... October 25, 2014 More than 50 ... Circle Reception on Monday at the home of Jim ... hear from guest speaker Dr. Winifred Lender on finding ... Dr. Lender, a Santa Barbara psychologist, author and Noozhawk ... benefits of living in the digital age. Our digital ...
(Date:10/25/2014)... QueenBeeTickets.com has a variety of tickets ... affordable prices. Bob Seger & The Silver Bullet Band ... Arena are going on sale October 25 and are ... to browse the selection of tickets for Bob Seger ... famous singer is touring North America beginning next month, ...
(Date:10/25/2014)... (HealthDay News) -- Interrupting blood supply to an arm or ... associated with the surgery, according to a new study. ... supply to the heart to be able to operate on ... reduce its ability to produce energy because it doesn,t get ... large muscle, such as an arm or a leg, the ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Current osteoporosis screening guidelines ... women at risk for osteoporosis-related fractures, a new ... fractures, we need tools that help us accurately ... that we can target these at-risk people for ... of medicine in the division of general internal ...
Breaking Medicine News(10 mins):Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 2Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... grow a lot in 13,years, and a successful ... diagnostic sleep testing and sleep apnea treatment, is ... moving into new corporate,offices. Recently named one ... America, SleepQuest has moved its headquarters from Redwood,City ...
... Center in Portland Finds BSGI Capable of Significantly ... Changing Clinical Management in Patients, NEWPORT ... significantly changed patient management at one breast,center in Portland, Oregon. ... reported that although still fairly new to,BSGI, the procedure has ...
... Study finds men with more than 3 kids are more ... A young, trim farmer with four or more children: According to ... to reach 100 years of age. , The research, based largely ... off excess weight in youth, farming and fathering a large number ...
... therapeutic human drugs using modified mushrooms may help mount ... to plant pathologists who have received a federal grant ... of plant pathology at Penn State and holder of ... "We are looking to address several public health issues ...
... data today at the 60th Annual Meeting of ... that doing the right kind of brain exercise can ... , Dr. Elizabeth Zelinski of the University of Southern ... study (Improvement in Memory with Plasticity-based Adaptive Cognitive Training) ...
... LOS ANGELES, Calif., Nov. 19 ,Natrol, Inc, (Nasdaq: ... of,nationally branded nutritional products, and Gener8Xion Entertainment, Inc.,(OTC ... have executed a letter of intent for a ... Division. Natrol intends to,exclusively license the "Living Pure" ...
Cached Medicine News:Health News:SleepQuest Continues Growth, Moves Headquarters 2Health News:Breast-Specific Gamma Imaging (BSGI) Changes Patient Care Management 2Health News:Farming, Fatherhood Hallmarks of Men Who Live to 100 2Health News:Farming, Fatherhood Hallmarks of Men Who Live to 100 3Health News:Farming, Fatherhood Hallmarks of Men Who Live to 100 4Health News:Mushrooms may aid rapid vaccine response 2Health News:New research on aging and cognitive training presented at GSA's Annual Meeting 2Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 2Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 3Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 4
0.5 mm, 1 x 2 teeth set at 45 degrees and 6 mm tying platform. Serrated handle with polished finish....
Two 2.75 mm long tips separated 1 mm with 1 x 2 teeth. Serrated handle with dull finish....
1 x 2 teeth and 5.5 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm....
Colibri style tips with 0.12 mm, 1 x 2 teeth. Round knurled handle with alignment pin and polished finish....
Medicine Products: